FilingReader Intelligence
Darentang profit surges 193% on strategic asset sale
August 14, 2025 at 05:11 PM UTC•By FilingReader AI
Darentang reported net profit of 1.93bn yuan, up 193%, primarily from selling a 12% stake in Sino-American Tianjin SK&F Pharmaceutical for 1.31bn yuan after-tax proceeds.
Revenue fell 33% to 2.65bn yuan due to de-consolidation of Tianjin ZhongXin Pharmaceutical.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
SSE:600329•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Tianjin ZhongXin Pharmaceutical Group Corp publishes news
Free account required • Unsubscribe anytime